For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?  

Endometrial cancer incidence is increasing in the United States, and very little improvement in survival has been noted for advanced disease until recently. Monotherapy with immune checkpoint inhibitors have offered hope for patients with recurrence, and the recent publication of GY018 and the RUBY ...

Unfortunately, the answer to this question cannot be supported by either of the two studies. However, when looking at the survival curves from both GY018 and RUBY, the differences between the two curves appear right around or after cycle 6 of chemotherapy. Yet we do not know if this difference was "...